Skip to main content

Blog

Welcome to The Happy Lungs Project Blog. Check out these blog posts from our Scientific Advisory Board members and other partners from the scientific community explaining the latest RET research.

We seek to support researchers and clinicians in their work toward a cure for Non-Small Cell Lung Cancer caused by the RET mutation. We also aim to provide community resources and events to support finding a cure for RET Positive Lung Cancer. On this blog, you will find information about our research, RET clinical trials, patient stories and upcoming events.

We would like to also welcome our guest blogger, Anthony “Nino” Sireci, M.D., vice president, clinical biomarker and diagnostics development at Lilly. Read Nino’s News.

Filter

Current Treatment Options for RET Lung Cancer
REt positive lung cancer treatment options in 2024, ret gene and ret fusions
Current Treatment Options for RET Lung Cancer

Current Treatment Options for RET Lung Cancer

Lung cancer staging matters. Why? So your doctor can properly assess the spread of disease…
June 5, 2024
The Happy Lungs Project Update: July 2024
RET positive lung cancer support
The Happy Lungs Project Update: July 2024

The Happy Lungs Project Update: July 2024

Cancer drug resistance means that a tumor no longer responds to anticancer drugs that were…
July 14, 2024
Immunotherapy and RET Lung Cancer
Immunotherapy cancer treatment for ret lung cancer
Immunotherapy and RET Lung Cancer

Immunotherapy and RET Lung Cancer

Cancer drug resistance means that a tumor no longer responds to anticancer drugs that were…
July 8, 2024
Results From Our Spring 2024 Survey
RET lung cancer research survey 2024
Results From Our Spring 2024 Survey

Results From Our Spring 2024 Survey

What we learned, and what’s next: Scientific research can be confusing and overwhelming, and that’s…
May 29, 2024
IASLC Targeted Therapies Recap
together separately live stream
IASLC Targeted Therapies Recap

IASLC Targeted Therapies Recap

#TogetherSeparately: live virtual meetup to summarize data presented on February’s IASLC Targeted Therapies Meeting. March 13 at 3PM…
March 11, 2024
RET inhibitor Granted Fast Track by FDA
elipses pharma ep0031
RET inhibitor Granted Fast Track by FDA

RET inhibitor Granted Fast Track by FDA

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Ellipses Pharma…
March 11, 2024
The Harmonic™ Clinical Trial for Never Smokers
harmonic never smoker lung cancer trial
The Harmonic™ Clinical Trial for Never Smokers

The Harmonic™ Clinical Trial for Never Smokers

New clinical trial for never smokers: The Harmonic™ clinical trial The Harmonic™ clinical trial is…
March 9, 2024
2023 RET Cancer Research Update
ret cancer research 2023
2023 RET Cancer Research Update

2023 RET Cancer Research Update

2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
December 18, 2023
Exciting Preclinical Results About Vepafestinib
RET lung cancer study 2023
Exciting Preclinical Results About Vepafestinib

Exciting Preclinical Results About Vepafestinib

New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06).  Vepafestinib showed selectivity…
October 10, 2023